Johnson & Johnson receives USFDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
Johnson & Johnson that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200






















